# Flowmedi Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/flowmedi-co

- Industry: Biotechnology
- Headquarters: Pohang, South Korea
- Website: www.flowmedi.co.kr
- Total disclosed funding: $0.3M
- Latest round: Seed (Sep 14, 2023)
- Investors on record: 1

## About

Based in Pohang, South Korea, and founded in 2022, Flowmedi Co., Ltd. is a developer of new drugs and treatments for incurable brain and metabolic diseases. In November 2023, FlowMedi raised seed funding from new investor Korea Tech Incubator for Startup. being selected for Accelerator Investment-Driven Tech Incubator Program. Financial terms of the deal were not disclosed. As of September 2023, the company’s CEO is Kim Chun-gil. The company’s flagship product, FLENCAP, ensures stability and efficiency, proven through rigorous testing. Additionally, Flowmedi Co., Ltd. utilizes FM-Micro, a microparticle drug delivery system designed to protect drugs and precisely control their release. FM-Nano, another product, involves nanoparticle drug delivery technology, enhancing drug penetration into cellular units with precise size control. Lastly, FM-Smart leverages nanorobot technology to autonomously manipulate drug delivery vehicles, offering intensive treatment in disease areas such as bladder cancer and coronary artery disease. In addition, the company’s pipeline products are microfluidic devices, including 3D-printed microfluidic reactors, droplet generators, and uniform flow rate distributors. These innovative devices are designed to improve drug particle holding rates, enable continuous batch manufacturing of uniform capsules, and facilitate various laboratory experiments. Additionally, FlowMedi has ventured into nanotechnology, with patents for triple-response nanomotors and self-propelled hybrid amorphous nanomotors, which have applications in cancer cell photothermia.

## Funding rounds

- Seed, Sep 14, 2023, $0.3M — POSTECH Holdings

## Investors

- POSTECH Holdings (https://capitalatlas.ai/funds/postech-holdings) — Seed